Clinical trialPhase 3Completed
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
- Outcome
- Primary endpoint: statistically significant difference (Hazard Ratio (HR) 0.47 (95% CI 0.30 to 0.73); p < 0.001, as posted; no threshold posted, 0.05 used)
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- June 2006
- Ended
- April 2013
- Enrollment
- 264 participants
- Sites
- 71
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor type
- Industry
- Results posted
- 18 February 2015
- Last update
- 5 March 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Primary endpoint: statistically significant difference (Hazard Ratio (HR) 0.47 (95% CI 0.30 to 0.73); p < 0.001, as posted; no threshold posted, 0.05 used)As posted on ClinicalTrials.gov ↗, registry record of 5 March 2025
- PFS
- Progression-Free Survival (PFS)Lanreotide (Autogel Formulation): NA (NA to NA), n = 101 (Not available as median not reached during the 96 week fixed duration study.)Placebo: 72 (48.6 to 96.0), n = 103Lanreotide (Autogel Formulation) vs Placebo: Hazard Ratio (HR) 0.47 (95% CI 0.30 to 0.73); p < 0.001; Log Rank (statistically significant against 0.05 (no threshold posted); outcome 1, analysis 1)Values: median Weeks, 95% Confidence IntervalTime frame: From randomisation up to the last tumour assessment (scheduled at 96 weeks). Radiological scans were performed every 12 weeks during the first year and every 24 weeks during the second year
- Participants
- Lanreotide (Autogel Formulation): 101 started, 85 completedPlacebo: 103 started, 86 completed
- Serious adverse events
- Lanreotide (Autogel Formulation): 25 of 101Placebo: 32 of 103Participants with at least one serious adverse event, of those at risk, as posted
- Reported in
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. DOI 10.1056/nejmoa1316158↗ Linked as this trial’s results paper. The numbers above are the registry’s, not the paper’s.
5 secondary outcomes
- Percentage of Patients Alive & Without Disease Progression
- Week 48: Lanreotide (Autogel Formulation) 66, n=101; Placebo 49, n=103 [Percentage of participants] (first of 2 rows)
- Pharmacokinetic Profile of Lanreotide
- At Week 4 predose (n=81): Lanreotide (Autogel Formulation) 2.5 (0.46), n=101 [mean ng/mL, Standard Deviation] (first of 7 rows)
- Change in the Global Health Status Quality of Life Assessment
- Lanreotide (Autogel Formulation) -5.2 (3.7), n=95; Placebo -4.9 (3.7), n=98 [LS mean score on a scale, Standard Error]
- Percentage of Patients With a Greater Than or Equal to 50% Decrease in Plasma Chromograni…
- Lanreotide (Autogel Formulation) 42.2, n=64; Placebo 4.7, n=64 [percentage of participants]
- OS · Percentage of Patients Still Alive Based on Available Overall Survival Data
- Lanreotide (Autogel Formulation) 84, n=101; Placebo 77, n=103 [percentage of participants]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival (PFS) [From randomisation up to the last tumour assessment (scheduled at 96 weeks). Radiological scans were performed every 12 weeks during the first year and every 24 weeks during the second year]. Median, Weeks (95% Confidence Interval). Lanreotide (Autogel Formulation) (n=101): NA (NA to NA) [Not available as median not reached during the 96 week fixed duration study.]; Placebo (n=103): 72 (48.6 to 96.0). Analysis, Lanreotide (Autogel Formulation) vs Placebo: Hazard Ratio (HR) 0.47 (95% CI 0.30 to 0.73); p=<0.001; Log Rank; superiority or other legacy.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Patients Alive & Without Disease Progression [Week 48 & 96]. Number, Percentage of participants. Week 48: Lanreotide (Autogel Formulation) (n=101): 66; Placebo (n=103): 49. Week 96: Lanreotide (Autogel Formulation) (n=101): 53; Placebo (n=103): 25.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Pharmacokinetic Profile of Lanreotide [Week 4, 12, 24, 36, 48, 72, 96]. Mean, ng/mL (Standard Deviation). At Week 4 predose (n=81): Lanreotide (Autogel Formulation) (n=101): 2.5 (0.46). At Week 12 predose (n=87): Lanreotide (Autogel Formulation) (n=101): 5.0 (0.42). At Week 24 predose (n=74): Lanreotide (Autogel Formulation) (n=101): 6.1 (0.44). At Week 36 predose (n=67): Lanreotide (Autogel Formulation) (n=101): 6.2 (0.39). At Week 48 predose (n=62): Lanreotide (Autogel Formulation) (n=101): 6.6 (0.45). At Week 72 predose (n=52): Lanreotide (Autogel Formulation) (n=101): 6.8 (0.44). At Week 96 predose (n=48): Lanreotide (Autogel Formulation) (n=101): 6.6 (0.39).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Change in the Global Health Status Quality of Life Assessment [Week 12 to Week 96 (last visit)]. Least Squares Mean, score on a scale (Standard Error). Lanreotide (Autogel Formulation) (n=95): -5.2 (3.7); Placebo (n=98): -4.9 (3.7).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Patients With a Greater Than or Equal to 50% Decrease in Plasma Chromogranin A (CgA) Levels [Week 12 to Week 96 (last visit)]. Number, percentage of participants. Lanreotide (Autogel Formulation) (n=64): 42.2; Placebo (n=64): 4.7.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Patients Still Alive Based on Available Overall Survival Data [Randomisation to death or last visit, up to 321 weeks]. Number, percentage of participants. Lanreotide (Autogel Formulation) (n=101): 84; Placebo (n=103): 77.
Papers 7
- Registry-listed results paperLanreotide in metastatic enteropancreatic neuroendocrine tumors. DOI 10.1056/nejmoa1316158↗
- Builds on itResponse heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors. DOI 10.2217/fon-2022-1137↗
- Builds on itImpact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. DOI 10.3390/cancers14010069↗
- Builds on itLanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label … DOI 10.1007/s12020-020-02475-2↗
- Builds on itPrognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. DOI 10.1097/cad.0000000000000909↗
- Builds on itTumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumor… DOI 10.1186/s12885-018-5257-x↗
- Builds on itLong-term disease control of a pancreatic neuroendocrine tumor with lanreotide autogel(®): a case report. DOI 10.1159/000368207↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.